Generate Biomedicines, Inc. (GENB) Ownership
GENB ownership summary
as of October 18, 2026- Institutions
- 79.0% of shares outstanding
- Insiders
- 14.05% of shares outstanding
- Shares outstanding
- 128.4M
- Float
- 60.4M shares available to trade
- Short interest
- 9.92% 7.4M shares short
- Days to cover
- 6.27 short interest up 3.3% vs prior month
- Institutions 79.02%
- Insiders 14.05%
- Other investors 6.93%
GENB top institutional holders
20 largest| # | Holder | % of shares | Shares | Value | Change | Reported |
|---|---|---|---|---|---|---|
| 1 | Flagship Ventures Management, Inc. | 48.83% | 62.7M | $757.7M | — | June 30, 2026 |
| 2 | FMR Inc | 4.07% | 5.2M | $63.1M | +1.0M (+23.8%) | June 30, 2026 |
| 3 | Capital World Investors | 3.28% | 4.2M | $51.0M | +211,483 (+5.3%) | June 30, 2026 |
| 4 | BRAIDWELL LP | 2.56% | 3.3M | $39.7M | −309,155 (−8.6%) | June 30, 2026 |
| 5 | T. Rowe Price Associates, Inc. | 1.68% | 2.2M | $26.1M | +46,994 (+2.2%) | June 30, 2026 |
| 6 | NORGES BANK | 1.63% | 2.1M | $25.3M | +2.1M (0.0%) | June 30, 2026 |
| 7 | ARCH VENTURE CORP | 1.51% | 1.9M | $23.5M | — | June 30, 2026 |
| 8 | Harbourvest Partners, LLC | 1.34% | 1.7M | $20.8M | — | June 30, 2026 |
| 9 | BlackRock Inc | 1.29% | 1.7M | $20.1M | +1.7M (0.0%) | June 30, 2026 |
| 10 | Baker Bros Advisors LP | 1.11% | 1.4M | $17.2M | — | June 30, 2026 |
| 11 | JPMorgan Chase & Co | 1.10% | 1.4M | $17.0M | −1.5M (−52.2%) | June 30, 2026 |
| 12 | Deep Track Capital, LP | 1.04% | 1.3M | $16.1M | +1.3M (0.0%) | June 30, 2026 |
| 13 | ARK Investment Management LLC | 1.00% | 1.3M | $15.5M | +786,209 (+157.7%) | June 30, 2026 |
| 14 | Vanguard Capital Management, LLC | 0.88% | 1.1M | $13.7M | +1.0M (+762.6%) | June 30, 2026 |
| 15 | Harvard Management Co Inc | 0.87% | 1.1M | $13.4M | — | June 30, 2026 |
| 16 | NVIDIA Corp | 0.65% | 833K | $10.1M | — | June 30, 2026 |
| 17 | Davern Capital Partners, L.P. | 0.64% | 825K | $10.0M | +232,879 (+39.4%) | June 30, 2026 |
| 18 | Siren, L.L.C. | 0.57% | 736K | $8.9M | — | June 30, 2026 |
| 19 | Geode Capital Management, LLC | 0.57% | 735K | $8.9M | +616,760 (+521.6%) | June 30, 2026 |
| 20 | State Street Corp | 0.41% | 527K | $6.4M | +526,565 (0.0%) | June 30, 2026 |
Value at the latest close. Change = shares bought or sold in the latest quarterly filing (13F). In the top 20, 11 holders added 9.5M shares and 2 cut 1.8M.
GENB top mutual fund and ETF holders
20 largest| # | Holder | % of shares | Shares | Value | Change | Reported |
|---|---|---|---|---|---|---|
| 1 | American Funds SMALLCAP World A | 2.92% | 3.8M | $45.4M | +102,596 (+2.8%) | June 30, 2026 |
| 2 | Fidelity Growth Company Fund | 1.70% | 2.2M | $26.4M | +1.3M (+159.8%) | August 31, 2026 |
| 3 | T. Rowe Price Health Sciences | 1.39% | 1.8M | $21.6M | — | August 31, 2026 |
| 4 | ARK Genomic Revolution ETF | 1.21% | 1.5M | $18.7M | +3,786 (+0.2%) | September 30, 2026 |
| 5 | Vanguard MStar Total Stk Mkt Idx Invest | 0.64% | 817K | $9.9M | — | August 31, 2026 |
| 6 | Fidelity Growth Company K6 | 0.54% | 696K | $8.4M | +459,847 (+194.8%) | August 31, 2026 |
| 7 | JPMorgan Small Cap Growth A | 0.43% | 556K | $6.7M | −16,395 (−2.9%) | August 31, 2026 |
| 8 | Fidelity Series Growth Company | 0.43% | 556K | $6.7M | +336,421 (+153.5%) | August 31, 2026 |
| 9 | ARK Venture D | 0.25% | 317K | $3.8M | +317,120 (0.0%) | April 30, 2026 |
| 10 | Eaton Vance Worldwide Health Sci A | 0.24% | 309K | $3.7M | — | August 31, 2026 |
| 11 | JPMorgan U.S. Tech Leaders ETF | 0.22% | 283K | $3.4M | — | September 30, 2026 |
| 12 | Fidelity Small Cap Index | 0.21% | 267K | $3.2M | +2,939 (+1.1%) | July 31, 2026 |
| 13 | JPMorgan Small Cap Blend A | 0.14% | 178K | $2.2M | −3,273 (−1.8%) | August 31, 2026 |
| 14 | American Funds U.S. Sm & Md Cp Eq R-6 | 0.14% | 174K | $2.1M | +26,007 (+17.5%) | June 30, 2026 |
| 15 | ALPS Medical Breakthroughs ETF | 0.13% | 170K | $2.1M | — | September 30, 2026 |
| 16 | Capital Group FG GOpp LUX ZL | 0.11% | 143K | $1.7M | −8,388 (−5.6%) | June 30, 2026 |
| 17 | Vanguard Russell 2000 ETF | 0.11% | 141K | $1.7M | +3,412 (+2.5%) | August 31, 2026 |
| 18 | Schwab US Small-Cap ETF™ | 0.10% | 134K | $1.6M | +90 (+0.1%) | September 30, 2026 |
| 19 | Fidelity Extended Market Index | 0.10% | 128K | $1.5M | −686 (−0.5%) | August 31, 2026 |
| 20 | American Funds IS® SMALLCAP World 1 | 0.08% | 104K | $1.3M | +103,973 (0.0%) | June 30, 2026 |
Funds report holdings monthly or quarterly; dates differ by fund.
Who owns GENB
Institutional investors own 79.0% of Generate Biomedicines's shares and insiders 14.05%. The largest holder is Flagship Ventures Management, Inc. with 48.83% of the shares (62.7M), as of June 30, 2026. Among the top 20 institutions, 11 added shares and 2 reduced their stake in the latest filings. Short interest is 9.92% of the float, or 6.27 days of average trading volume.
Related: GENB analyst forecast, GENB key metrics. See the GENB stock overview for the latest quote and news.
GENB ownership FAQ
Who owns the most Generate Biomedicines stock?
The largest shareholders of Generate Biomedicines are Flagship Ventures Management, Inc. (48.83%), FMR Inc (4.07%), Capital World Investors (3.28%), BRAIDWELL LP (2.56%), T. Rowe Price Associates, Inc. (1.68%).
What percentage of Generate Biomedicines is owned by institutions?
Institutions hold 79.0% of Generate Biomedicines's shares outstanding; insiders hold 14.05%.
Which funds own Generate Biomedicines?
The largest fund holders of Generate Biomedicines are American Funds SMALLCAP World A (2.92%), Fidelity Growth Company Fund (1.70%), T. Rowe Price Health Sciences (1.39%), ARK Genomic Revolution ETF (1.21%), Vanguard MStar Total Stk Mkt Idx Invest (0.64%).
What is Generate Biomedicines's short interest?
7.4M shares of Generate Biomedicines were sold short, 9.92% of the float; at the average daily volume it would take 6.27 days to cover.
How many shares of Generate Biomedicines are outstanding?
Generate Biomedicines has 128.4M shares outstanding, of which 60.4M are in the public float.